BlackRock-advised Funds > iShares Trust
iShares Genomics Immunology and Healthcare ETF
$131.91M
Avg Monthly Net Assets
$166.87M
Total Assets
$26.47M
Total Liabilities
$140.40M
Net Assets
iShares Genomics Immunology and Healthcare ETF is an Exchange-Traded Fund in iShares Trust
from BlackRock-advised Funds,
based in California,
United States of America.
The fund has one share class
and monthly net assets of $131.91M.
On September 27th, 2024 it reported 52 holdings, the largest
being BlackRock Funds III (9.4%), Roche Holding AG (4.7%) and Gilead Sciences Inc (4.6%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| iShares Genomics Immunology and Healthcare ETF | C000212225 | ARCX | IDNA |
Holdings
From latest NPORT-P, filed September 27th, 2024 for period ending July 31st, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Long | Equity-common | US | $1M | 67K | 0.85 |
| AbCellera Biologics Inc | Long | Equity-common | CA | $1M | 318K | 0.74 |
| ABLBio Inc | Long | Equity-common | KR | $998K | 48K | 0.71 |
| Arcellx Inc | Long | Equity-common | US | $4M | 62K | 2.72 |
| Arcturus Therapeutics Holdings Inc | Long | Equity-common | US | $889K | 38K | 0.63 |
| Arcus Biosciences Inc | Long | Equity-common | US | $1M | 74K | 0.87 |
| Beam Therapeutics Inc | Long | Equity-common | US | $4M | 118K | 2.67 |
| BeiGene Ltd | Long | Equity-common | KY | $6M | 452K | 4.10 |
| BioCryst Pharmaceuticals Inc | Long | Equity-common | US | $2M | 306K | 1.59 |
| BioNTech SE | Long | Equity-common | DE | $5M | 55K | 3.38 |
| BlackRock Cash Funds: Institutional, SL Agency Shares (BlackRock Funds III) | Long | Short-term investment vehicle | US | $13M | 13M | 9.38 |
| BlackRock Cash Funds: Treasury, SL Agency Shares (BLACKROCK CASH FUNDS TREASURY SL AGENCY SHARES) | Long | Short-term investment vehicle | US | $120K | 120K | 0.09 |
| Blueprint Medicines Corp | Long | Equity-common | US | $2M | 21K | 1.63 |
| CRISPR Therapeutics AG | Long | Equity-common | CH | $2M | 28K | 1.14 |
| CureVac NV | Long | Equity-common | NL | $545K | 144K | 0.39 |
| Dynavax Technologies Corp | Long | Equity-common | US | $2M | 201K | 1.60 |
| Editas Medicine Inc | Long | Equity-common | US | $684K | 127K | 0.49 |
| Exelixis Inc | Long | Equity-common | US | $6M | 252K | 4.21 |
| Genmab A/S | Long | Equity-common | DK | $6M | 20K | 3.97 |
| Geron Corp | Long | Equity-common | US | $4M | 772K | 2.61 |
| Gilead Sciences Inc | Long | Equity-common | US | $6M | 85K | 4.62 |
| Ginkgo Bioworks Holdings Inc | Long | Equity-common | US | $822K | 2M | 0.59 |
| GSK PLC | Long | Equity-common | GB | $5M | 266K | 3.68 |
| ImmunityBio Inc | Long | Equity-common | US | $1M | 238K | 0.87 |
| Incyte Corp | Long | Equity-common | US | $6M | 93K | 4.32 |
| Intellia Therapeutics Inc | Long | Equity-common | US | $857K | 33K | 0.61 |
| Iovance Biotherapeutics Inc | Long | Equity-common | US | $3M | 345K | 2.15 |
| Ligand Pharmaceuticals Inc | Long | Equity-common | US | $3M | 27K | 2.10 |
| MacroGenics Inc | Long | Equity-common | US | $337K | 90K | 0.24 |
| Merck & Co Inc | Long | Equity-common | US | $5M | 42K | 3.40 |
| Moderna Inc | Long | Equity-common | US | $4M | 37K | 3.10 |
| Novavax Inc | Long | Equity-common | US | $3M | 206K | 1.88 |
| Nurix Therapeutics Inc | Long | Equity-common | US | $2M | 88K | 1.37 |
| Nxera Pharma Co Ltd | Long | Equity-common | JP | $286K | 26K | 0.20 |
| OmniAb Inc | Long | Equity-common | US | $702K | 147K | 0.50 |
| OMNIAB INC | Long | Equity-common | US | $0.19 | 19K | 0.00 |
| OMNIAB INC | Long | Equity-common | US | $0.19 | 19K | 0.00 |
| Ono Pharmaceutical Co Ltd | Long | Equity-common | JP | $2M | 116K | 1.22 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $6M | 6K | 4.23 |
| REVOLUTION Medicines Inc | Long | Equity-common | US | $6M | 137K | 4.45 |
| Roche Holding AG | Long | Equity-common | CH | $7M | 20K | 4.70 |
| Sanofi SA | Long | Equity-common | FR | $6M | 56K | 4.11 |
| Sarepta Therapeutics Inc | Long | Equity-common | US | $6M | 45K | 4.53 |
| SpringWorks Therapeutics Inc | Long | Equity-common | US | $4M | 102K | 2.60 |
| Takeda Pharmaceutical Co Ltd | Long | Equity-common | JP | $6M | 204K | 4.09 |
| ToolGen Inc | Long | Equity-common | KR | $494K | 9K | 0.35 |
| Twist Bioscience Corp | Long | Equity-common | US | $5M | 86K | 3.41 |
| uniQure NV | Long | Equity-common | NL | $563K | 74K | 0.40 |
| Valneva SE | Long | Equity-common | FR | $588K | 165K | 0.42 |
| Vir Biotechnology Inc | Long | Equity-common | US | $1M | 137K | 0.99 |
| XAV HEALTH CARE SEP24 (Chicago Mercantile Exchange) | Derivative-equity | US | $8K | – | 0.01 | |
| Xencor Inc | Long | Equity-common | US | $421K | 21K | 0.30 |
Address
iShares Trust
400 Howard Street
San Francisco
California
94105
United States of America
Websites
Directors
John E. Kerrigan
Richard L. Fagnani
Robert S. Kapito
Drew E. Lawton
Laura F. Fergerson
Stephen Cohen
John E. Martinez
Madhav V. Rajan
Jane D. Carlin
Cecilia H. Herbert
James Lam
Transfer Agents
JPMorgan Chase Bank, N.A.
Pricing Services
ICE Data Pricing & Reference Data, LLC
Custodians
JPMorgan Chase Bank, N.A.
Shareholder Servicing Agents
N/A
Admins
JPMorgan Chase Bank, N.A.
Brokers
Goldman Sachs & Co. LLC
BNP Paribas Securities Corp.
BofA Securities, Inc.
Jefferies LLC
Citigroup Global Markets Inc.
Barclays Capital, Inc.
UBS Securities LLC